Reflecting on 2025: Key Milestones for Our Community

As we look back on 2025, we’re proud to share an overview of the significant milestones that shaped the year for our community. This year brought important progress across our core conditions: heterozygous familial hypercholesterolaemia (HeFH), homozygous familial hypercholesterolaemia (HoFH), elevated Lp(a), and familial chylomicronaemia syndrome (FCS). 

We’ve compiled a document that tracks the major regulatory updates, clinical trial results, events, and community projects from the past year. It’s designed to provide patients, caregivers, and healthcare professionals with a clear picture of the advances that are moving the field forward. Importantly, the document has been reviewed by leading experts to ensure accuracy and relevance. 

What’s Inside 

• Regulatory Milestones and Guidelines: Key approvals, indication updates and clinical guidelines that impact treatment and care. 

• Clinical Trials: Notable results, ongoing studies, and upcoming trials for each condition. 

• Events, Projects and Collaborations: Efforts advancing research, awareness, and patient support. 

This document highlights the collective efforts of researchers, clinicians, patient advocates, and the broader community that continue to improve outcomes for individuals affected by these conditions. 

We invite you to explore the full 2025 milestones document. 

📄 Download the 2025 Milestones Document

(This document contains some links directing to external content created by pharmaceutical companies and sharing it does not imply endorsement of any product, treatment, or organisation.)